What is the price of Orchard Therapeutics plc (ORTX)

The price of Orchard Therapeutics plc (ORTX) is $16.70

What is the market cap of Orchard Therapeutics plc (ORTX)

The market cap of Orchard Therapeutics plc (ORTX) is $210.34M

Orchard Therapeutics plc (ORTX) P/B Ratio

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.

Year	P/B Ratio	Change
Not enough data for the provided dates.

Year

P/B Ratio

Change

Not enough data for the provided dates.

Company	P/B Ratio	P/B Ratio Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	6.828	-	US
Argenx SE ARGX.US	7.5116	-	NL
Moderna, Inc. MRNA.US	8.2199	-	US
CSL Limited CSL.AX	3.9942	-	AU
Lonza Group AG LONN.SW	-	-	CH

Company

P/B Ratio

P/B Ratio Difference

Country